22.02.2024 - Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million XPHOZAH launch off to a strong start, .
08.01.2024 - Company achieved significant commercial progress in 2023 IBSRELA now expected to generate greater than $1.0 billion in annual U.S. net product sales revenue at peak Webcast scheduled for 7:00 PM ET / 4:00 PM PT to discuss IBS-C Market WALTHAM, . Seite 1
06.11.2023 - XPHOZAH is the first and only FDA approved phosphate absorption inhibitor Best-in-class patient services programs support patient access and affordability for XPHOZAH patients WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) - Ardelyx, Inc. . Seite 1
03.11.2023 - WALTHAM, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical . Seite 1
13.10.2023 - WALTHAM, Mass., Oct. 13, 2023 (GLOBE NEWSWIRE) - Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical .